FDA warns Arizona firm over numerous alleged disease claims

By Hank Schultz

- Last updated on GMT

©Getty Images - Ildo Frazao
©Getty Images - Ildo Frazao

Related tags regulations Regulation disease claims

An Arizona supplement marketer has been warned by FDA over claims relating to blood sugar management, stress relief, immunity and more.

The US Food and Drug Administration sent a warning letter to ICL Health, LLC, based in Tucson.  The company markets several supplements, all attributed to the company’s principal, Dr James L. Wilson, ND.

Among the products cited in the warning letter are Good Sugar, a blood sugar management product featuring minerals and herbs, Super Immune Space Sprinkles, an immunity product aimed at children, Super Immune Space Sprinkles, Cortisol Stress Reset, Nat-Stim and others.

The warning letter claims that the company was making claims to treat a host of conditions, including alcoholism, autoimmune diseases, fibromyalgia, depression and rheumatoid arthritis.

Specific claims

Among some of the many specific claims for ingredients and formulas cited by the Agency were these:

  • “Some researchers believe this [L-Lysine’s] ability to save off outbreaks also helps in the prevention of many other diseases related to cranial nerves such as migraines, Meniere’s disease, and Bell’s palsy.”
  • “[Ingredient(s) in Dr. Wilson’s Nat-Stim are] essential for immune function . . . . Stress and Immune Function . . . With chronic stress, this cortisol-related decrease in immune function can leave you more susceptible to colds, flu and other infections, and potentially make you more vulnerable to serious illness and degenerative disease down the road, as well as to the development of allergies and autoimmune disorders.”
  • “Can people with diabetes or metabolic syndrome take Dr. Wilson’s Good Sugar? . . . Diabetics and people with metabolic syndrome may find that Good Sugar . . . helps them feel their best.”

The warning letter resulted from a review of the company’s various websites, not a physical inspection.  FDA had given the company 15 days to respond from the issuance of the letter, which was dated Sept. 20, 2021.  The letter was posted on the FDA website on Oct. 5.

Related news

Show more

Related products

show more

Harness the power of algae for omega-3 innovation

Harness the power of algae for omega-3 innovation

Content provided by dsm-firmenich | 18-Jun-2024 | Insight Guide

Algal-sourced omega-3s have limitless potential, able to scale to meet the needs of our planet’s population with twice the potency – naturally – and all...

Innovate with EpiCor Postbiotic!

Innovate with EpiCor Postbiotic!

Content provided by Cargill | 10-Jun-2024 | White Paper

Upgrade your innovation with EpiCor® Postbiotic! EpiCor® is an innovative, science-backed postbiotic ingredient clinically shown to support immune health....

The solutions to botanical supply chain challenges

The solutions to botanical supply chain challenges

Content provided by Ayana Bio | 05-Jun-2024 | Infographic

Many botanicals continue to face supply chain challenges, from the surging demand for stress-relieving adaptogens and immune-support ingredients to the...

Ride the next wave of omega-3 innovation

Ride the next wave of omega-3 innovation

Content provided by dsm-firmenich | 01-Jun-2024 | Insight Guide

Fish oil supplies can’t scale to meet the needs of the planet’s growing population, but life’s®OMEGA can.

Related suppliers

Follow us

Products

View more

Webinars